Pharmacokinetics and pharmacodynamics of anticancer agents used in gynaecological oncology

CME Journal of Gynecologic Oncology

Volumn 6, Issue 1, 2001, Pages 5-16

  Atta, H ^a   Beijnen, J H ^a   Vermorken, J B ^a   Schellens, J H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Anticancer agents; Carboplatin; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Gynaecological cancers; Models; Paclitaxel; Pharmacodynamics; Pharmacokinetics; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PACLITAXEL; TENIPOSIDE; TOPOTECAN;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MONITORING; GYNECOLOGIC CANCER; HUMAN; KIDNEY FAILURE; LINEAR SYSTEM; LIVER DYSFUNCTION; MAXIMUM TOLERATED DOSE; MODEL; NONLINEAR SYSTEM; PHARMACODYNAMICS; REVIEW;

EID: 0034899060     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
2. Pharmacodynamics in cancer therapy
3. Pharmacokinetic drug interactions with anticancer drugs
4. The role of pharmacokinetics in (combination) chemotherapy
5. Pharmacokinetics and cancer chemotherapy
6. Paclitaxel pharmacokinetics and pharmacodynamics
7. Nonlinear pharmacokinetics: Clinical Implications
8. Tailor-made chemotherapy for cancer patients
9. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
10. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function
11. Anticancer drug pharmacodynamics
12. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands
13. Computer simulation of leukemia therapy: Combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside
14. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency
15. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin
16. Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin
17. Chemotherapy of advanced ovarian cancer
18. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: A phase I trial
19. Clinical pharmacokinetics of carboplatin
20. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days
21. The use of the Calvert formula to determine the optimal carboplatin dosage
22. Utility of individualized carboplatin dosing alone and in combination regimens
23. Formula-based dosing for carboplatin
24. A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel
25. Platinum complexes in cancer medicine: Pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity
26. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
27. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
28. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
29. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin
30. Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's
31. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: A comparison of the performance of three formulae
32. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination
33. Prediction of carboplatin clearance from morphological and biological patient characteristics
34. Practical treatment guide for dose individualisation in cancer chemotherapy
35. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function
36. Prospective validation of a pharmacologically based dosing scheme for the cisdiamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum
37. Modeling toxicity and response in carboplatin-based combination chemotherapy
38. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
39. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin
40. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin
41. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer
42. Platinum analogue combination chemotherapy: Cisplatin and carboplatin - A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion
43. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
44. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with sub-optimal stage III and stage IV ovarian cancer: A Gynecologic Oncology Group study
45. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with sub-optimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)
46. Anthracycline antibiotics in cancer therapy. Focus on drug resistance
47. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans
48. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study
49. The role of anthracyclines in epithelial ovarian cancer
50. Epirubicin: A review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer
51. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
52. Interstrand DNA crosslinking induced by anthracyclines in turnout cells
53. Clinical pharmacokinetics of epirubicin
54. Comments on epirubicin
55. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy
56. Pharmacokinetics and toxicity of two schedules of high dose epirubicin
57. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue
58. Pharmaeokinetics of epirubicin in cancer patients
59. Epirubicin. Clinical pharmacology and dose-effect relationship
60. Pharmacokineties of epirubicin after intravenous administration: Experimental and clinical aspects
61. Pharmacokinetics of anthracyclines
62. Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration
63. Disposition of epirubicin and metabolites with repeated courses to cancer patients
64. Pharmacokinetics of new anthracyclines
65. A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer
66. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
67. Pharmacokinetics and metabolism of anthracyclines
68. Clinical pharmacokinetics of epirubicin: The importance of liver biochemistry tests
69. Chemotherapy with cisplatin, epirubicin, methotrexate in the treatment of locally advanced or metastatic transitional cell cancer of the bladder (TCC)
70. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: Preliminary evidence of a potentially common drug interaction
71. Paclitaxel plus epirubicin in advanced breast cancer
72. Topoisomerase inhibitors. A review of their therapeutic potential in cancer
73. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide
74. Etoposide protein binding in cancer patients
75. Pharmaco-kinetics of etoposide in patients with abnormal renal and hepatic function
76. The taxoids. Comparative clinical pharmacology and therapeutic potential
77. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer
78. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
79. Pharmacokinetics of high dose etoposide (VP 16-213)
80. Etoposide pharmacokinetics in patients with normal and abnormal organ function
81. Pharmacokinetics of VP 16-213 given by different administration methods
82. The effect of dose on the bioavailability of oral etoposide
83. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide
84. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study
85. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: A phase I study
86. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay
87. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer
88. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
89. Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity
90. Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer
91. Paclitaxel has moderate activity in squamous cervix cancer
92. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: A review with emphasis on the Gynecologic Oncology Group experience
93. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer
94. Primary chemotherapy in epithelial ovarian cancer
95. Review of phase II trials of Taxol (paelitaxel) in patients with advanced ovarian cancer
96. Paclitaxel (taxol)
97. Paelitaxel (Taxol) therapy in ovarian carcinoma
98. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103
99. Paclitaxel, carboplatin, and hexamethyl-melamine (taxehex) as first-line therapy for ovarian cancer
100. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
101. Taxanes: An overview of the pharmacokinetics and pharmacodynamics
102. Phase I clinical and pharmacokinetic study of taxol
103. Evaluation of the linearity of docetaxel pharmacokinetics
104. Pharmacokinetics of the taxanes
105. Preclinical pharmacokinetics of paclitaxel and docetaxel
106. Theoretical and practical aspects of paclitaxel scheduling
107. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
108. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors
109. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
110. Pharmacokinetics of paelitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial
111. Phase II study of the combination carboplatin and paelitaxel in patients with ovarian cancer
112. Clinical pharmacology of carboplatin administered in combination with paclitaxel
113. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
114. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
115. The mechanisms of DNA topoisomerases
116. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors
117. An overview of the clinical pharmacology of topotecan
118. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
119. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
120. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function
121. Oral topotecan: Bioavailablity and effect of food co-administration
122. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
123. Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan
124. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
125. Reduced albumin binding promotes the stability and activity of topotecan in human blood
126. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure
127. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
128. Clinical pharmacokinetics of topotecan
129. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
130. Topoisumerase 1 inhibitors: The relevance of prolonged exposure for present clinical development
131. Phase 1 and pharmacologic study of topotecan in patients with impaired renal function
132. Quality of pharmacokinetic research in oncology
133. Limited sampling models for topotecan pharmacokinetics
134. Limited-sampling models for anticancer agents
135. Limited sampling models for doxorubicin pharmacokinetics
136. Clinical pharmacology of anticancer agents in relation to formulations and administration routes